Fundz

Who to call at BioMarin Pharmaceutical, and when

Fundz watches for the moments BioMarin Pharmaceutical starts buying, and tells you who to reach.

  • An alert the day BioMarin Pharmaceutical raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at BioMarin Pharmaceutical, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at BioMarin Pharmaceutical. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease.

Oct 29, 2026

Contract Type

agreement

San RafaelBiotechnology

Description

BioMarin has signed an exclusive worldwide license agreement with GC Biopharma and Hanmi Pharm for the development and commercialization of HM15421/GC1134A, an enzyme replacement therapy for Fabry disease. The agreement includes an upfront payment of $70 million and further milestone payments and royalties.

Company Information

Company

BioMarin Pharmaceutical

Location

San Rafael, California, United States

About

BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions.

Related People

Claudia
Senior decision-maker at this company
••••••••@••••••••

See Claudia's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for BioMarin Pharmaceutical's next move

Learn about Strategic plan

BioMarin Pharmaceutical signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.